Caris Life Sciences has formed a partnership with Flatiron Health, a healthtech company that helps cancer centers deliver better care for patients.
Louisiana State University Health New Orleans, an NCI-NCORPS designated institution, and ConcertAI, LLC have formed a five-year partnership to improve the diversity of clinical trials and ensure broader clinical trial access throughout the Gulf South region.
A clinical trial led by clinicians at Georgetown Lombardi Comprehensive Cancer Center showed a remarkable 20% advantage in the two-year OS rate for people with advanced melanoma who first received immunotherapy (72% survival rate) versus those who initially got targeted therapies (52% survival rate). Progression-free survival, where the cancer is stable or improving, was also trending in favor of those who started on immunotherapy.
A new class of small molecule drugs, now in phase I clinical trials, is the first to target circadian clock proteins, which play a key role in the recurrence and spread of glioblastoma.
University of Minnesota Medical School researchers explored the possible biological mechanisms that could explain the association between being overweight or obese prior to pregnancy and the increased risk of acute lymphoblastic leukemia in children.
New findings by the ACS found cumulative economic losses from cigarette smoking topped $891 billion in 2020, or 4.3% of the U.S. Gross Domestic Product. The economic loss significantly outpaced the cigarette industry’s $92 billion revenue by nearly a ten-to-one ratio. The study was published today in the journal The Lancet Public Health.
From March through December 2020, more than 16,000 cancer deaths were due to complications of COVID-19 in the U.S., according to a new study led by researchers at the American Cancer Society.
Merck, known as MSD outside of the United States and Canada, today announced that Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, received four new approvals from Japan’s Ministry of Health, Labor and Welfare. The indications included TNBC, renal cell carcinoma, cervical cancer, and melanoma.
Andrew Chapman is the first geriatric oncology expert to run an NCI-designated cancer center. Ever.
Drawing on Charles Dickens, NCI Acting Director Douglas Lowy has a teaching moment for oncology: we live in the best of times as well as the worst of times, because only fragments of human society—both in the United States and in low- and middle-income countries—fully benefit from modern cancer care.
